Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study. - Wikidata - awgldk - TriplyDB

Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.

Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.

http://www.wikidata.org/entity/Q30750448

about

The Efficacy of Imrecoxib and Celecoxib in Axial Spondyloarthritis and Their Influence on Serum Dickopff-Related Protein 1 (DKK-1) Levels The current standard of care and the unmet needs for axial spondyloarthritis

P2860

Q33841187-76042417-AF3D-4E66-9D0B-14177972A5ED Q59134860-9071427E-0659-42AC-BA4B-C8F887D8C04C

P2860

Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.

http://www.wikidata.org/entity/Q30750448

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Is there a role for sulphasala ...... itudinal observational study.

@ast

Is there a role for sulphasala ...... itudinal observational study.

@en

type

label

Is there a role for sulphasala ...... itudinal observational study.

@ast

Is there a role for sulphasala ...... itudinal observational study.

@en

prefLabel

Is there a role for sulphasala ...... itudinal observational study.

@ast

Is there a role for sulphasala ...... itudinal observational study.

@en

P1433

Q30750448-918747B9-C88A-4E6E-AEC5-85400E739B7E

P1476

Q30750448-DAA483BA-2273-4DBE-9E36-910B7D2CF980

P2093

Q30750448-199AAE69-BB1A-4460-94DD-B4BC6D6F69E4

Q30750448-3D648FF0-461C-4310-9AA2-5D1D934443FC

Q30750448-86140AF0-BC50-44A1-8C81-2C9EBBF9FD46

Q30750448-BC6B4B7A-E789-4395-8B3B-A3B37E76D687

Q30750448-CBE16B30-C0E4-421D-A994-58D44F48C0B2

Q30750448-DCC512A0-967B-4098-8277-16F05C368463

Q30750448-F1CCAB12-ED88-4381-A260-112D77AA232E

P2860

Q30750448-1816712D-241B-404C-B127-16ABA09AEC4D

Q30750448-285CC05C-07A4-4B81-818D-AD737CB46F43

Q30750448-6B892029-D258-472C-A71D-BCCAFB237505

Q30750448-7BC55BB5-B482-4D6B-91A6-7A2215A254E0

Q30750448-7DED34F7-7D52-4EE3-B3A5-17C43DD7BD8A

Q30750448-86D60BA5-CE84-445A-B692-F454510CED75

Q30750448-A6BFF2A7-7115-4194-A03F-61DF87763BD3

Q30750448-B75E4184-C7CF-4CA2-A1ED-DCC82147270C

Q30750448-BAC05D78-1B81-4207-B939-CAAB596386F4

Q30750448-D653B392-E392-4C99-B5B6-389BAB398495

P304

Q30750448-571B47C6-8071-409C-A969-16A1EF92A34C

P31

Q30750448-7D1D7414-001D-41BF-9619-0D96F32D50CE

P356

Q30750448-71215062-21B5-418D-8A14-D1C1DF478E6A

P433

Q30750448-F70F1784-FA89-4D3C-B885-B5FEB3E9CD88

P478

Q30750448-126CCB65-38D1-4ED2-84E8-86589E96E1D6

P50

Q30750448-33E5FD41-87FF-49F4-A0B3-FBB7EBC869DE

Q30750448-76DD67BB-1EA5-44CB-B9BB-719B73885E7E

P577

Q30750448-2D185C3C-2433-4191-96FD-BE028ECEC760

P698

Q30750448-8A82458E-3DCC-45E6-9C23-40446361486E

P356

P1433

P1476

Is there a role for sulphasala ...... itudinal observational study.

@en

P2093

Ada Wierød

http://www.w3.org/2001/XMLSchema#string

Elisabeth Lie

http://www.w3.org/2001/XMLSchema#string

Erik Rødevand

http://www.w3.org/2001/XMLSchema#string

Karen M Fagerli

http://www.w3.org/2001/XMLSchema#string

Knut Mikkelsen

http://www.w3.org/2001/XMLSchema#string

Marte S Heiberg

http://www.w3.org/2001/XMLSchema#string

Synøve Kalstad

http://www.w3.org/2001/XMLSchema#string

P2860

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial.

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.

First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

The estimation of a preference-based measure of health from the SF-36.

Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study.

P304

1087-1094

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KET450

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Désirée van der Heijde

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24501243

http://www.w3.org/2001/XMLSchema#string